Sglt2 Inhibitor
No difference in CV autonomic neuropathy with dapagliflozin vs. glimepiride
Adults with type 2 diabetes experienced no difference in cardiovascular autonomic neuropathy measures or B-type natriuretic peptide levels after 12 weeks of dapagliflozin therapy vs. 12 weeks of glimepiride, according to trial data.
Workshop to discuss multispecialty concepts on managing diabetes with CV, renal disease
A group of leading experts in cardiology, endocrinology and nephrology will gather for a workshop to discuss best practices for managing diabetes with cardiorenal metabolic diseases, with the goal of creating a new consensus statement.
ADA updates standards of care to reflect new teplizumab, HF data
The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors.
Age, comorbidities, medication use among predictors for severe COVID-19 in diabetes
Older age, obesity, cardiovascular disease, and pre-hospitalization use of steroids and SGLT2 inhibitors are among the factors that increase the risk for severe COVID-19 for people with diabetes, according to a speaker.
Top in endocrinology: SGLT2 inhibitors, tirzepatide for type 2 diabetes
Two experts debated whether SGLT2 inhibitors should be used as a first-line therapy for patients with type 2 diabetes. This point-counter point was the top story in endocrinology last week.
Should SGLT2 inhibitors be first-line therapy for type 2 diabetes?
As far as SGLT2 inhibitors for first-line therapy in type 2 diabetes, the question should be, why not? What other drug class, apart from insulin, can be prescribed and it works immediately, without the need for titration? SGLT2 inhibitors are insulin-independent. There is no risk for hypoglycemia. There is no risk for weight gain. They work for everyone, as long as you have a kidney.
Diabetes drugs now ‘pillars of care’ for heart failure
Heart failure and type 2 diabetes are exquisitely intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat.
VIDEO: Updates in diabetes management
There are 2 to 3 million people with type 1 diabetes in the United States, and about half of them are managed by general internists, according to Guillermo E. Umpierrez, MD, MACP, president-elect of the American Diabetes Association.
Black, Asian, female patients less likely to receive SGLT2 inhibitor prescription
Black, Asian and female patients with type 2 diabetes are less likely to receive a prescription for an SGLT2 inhibitor compared with other groups, even when diagnosed with cardiovascular or kidney disease, a database analysis shows.
Dapagliflozin fails to prevent organ damage, death in adults hospitalized with COVID-19
Top-line data from the phase 3 DARE-19 trial show that the SGLT2 inhibitor dapagliflozin failed to prevent organ dysfunction and all-cause mortality among hospitalized patients with COVID-19 at risk for developing serious complications.